Gt biopharma announces executive leadership transition to implement next phase of strategic journey

Beverly hills, calif., nov. 8, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® platform, today announced a restructuring of its executive management team.
GTBP Ratings Summary
GTBP Quant Ranking